Other Sources Fund Early-Stage Alzheimer’s Research As Pharma Favors Later Stages
Could Approval Of Biogen’s Aducanumab Improve Risk Tolerance?
New data show that early-stage Alzheimer’s trials increasingly are sponsored by government and nonprofit organizations, while another review illustrates diversification of the clinical pipeline.
You may also be interested in...
After largely negative advisory committee meeting, a patient group held a listening session with the FDA to be sure their voices were heard during the review of Biogen's aducanumab.
Lilly reported positive results from a Phase II pivotal trial of donanemab, which targets a modified form of beta-amyloid called N3pG, and has a second pivotal Phase II study under way.
An FDA advisory committee panel were critical of the agency’s review package for Biogen's aducanumab, raising uncertainty about the prospects of approval.